fair bit of debate about whether ISN management can cut it and whether they are pushing it uphill to actually develop a business.
I for one would love a longer delay and for the company to go straight ot the Gen2 app device with full wheezometer ... i really dont see the benefit of them rolling out a diary app apart from tinkering with the interface in the real world ....
the wheeze software in the phone is their market and i'd hate to see them trying to waste publicity on an app that is a pretty empty shell at this stage.
the other factor is do they even have a business. without doubt the wheeze technology in a smartphone is revolutionary for at home monitoring of symptoms. it's a big picture plan, but with share price languishing they really need to get some buy in from investors or tie ups with big pharama soon so we are not all diluted to the max.
agree management has gone very quiet ...
still, read this and ponder whether we are not a takeover target once we get some traction. i think even without revenue what they have right now is worth 5 times the
current market cap.
http://www.healthcareitnews.com/news/mhealth-poised-explode-expert-says
holding. waiting
Add to My Watchlist
What is My Watchlist?